Novo Nordisk’s Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.
Original Source
Read the full article at Cnbc →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.